Crossject

Equities

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 11:35:23 2024-05-06 am EDT			5-day change	1st Jan Change
2.135 ^EUR	-4.26%		+3.39%	-57.04%

May. 03	Crossject: praised for extended agreement on Zepizure	CF
May. 02	Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe	CI

Crossject: improved ESG rating in the Gaïa ranking

September 11, 2023 at 04:16 am EDT

Crossject announces that it has improved its Gaïa rating in terms of ESG performance, with a score of 73/100 this year versus 60 in 2022 and 46 in 2021, demonstrating its 'commitment to sustainable development and responsible business practices'.

This ranking, whose data was compiled by EthiFinance ESG Ratings, demonstrates the pharmaceutical company's progress in the four areas concerned: governance, social, environment and external stakeholders.

Copyright (c) 2023 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about Crossject

Crossject: praised for extended agreement on Zepizure	May. 03	CF
Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe	May. 02	CI
CROSSJECT : We welcome the securing of the group’s financial needs	May. 02	AL
CROSSJECT : Patience is a virtue… hopefully	Apr. 03	AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
CROSSJECT : Invest Securities slightly reduces its target	Feb. 28	CF
CROSSJECT : Securing the financing needs	Feb. 28	AL
Crossject: share price falls after convertible bond issue	Feb. 27	CF
Crossject Société Anonyme announced that it expects to receive ?12 million in funding	Feb. 25	CI
CROSSJECT : No news is not always good news...	Feb. 08	AL
Crossject: strategy advances, but visibility worries	Feb. 07	CF
CROSSJECT : Marketing initiative in the US	Jan. 06	AL
Crossject: Syneos Health hired for Zepizure in the USA	Jan. 05	CF
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment	Jan. 05	MT
CROSSJECT : A new distribution agreement in Northern Europe	Jan. 03	AL
France's Crossject Inks New Commercialization Deal for Epileptic Seizure Therapy in Northern EU	Dec. 22	MT
Crossject: commercial agreement in Northern Europe	Dec. 22	CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe	Dec. 22	CI
CROSSJECT : H1 23: no surprises before the release of the detailed accounts in October	23-09-28	AL
Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Crossject: improved ESG rating in the Gaïa ranking	23-09-11	CF
Crossject: manufacturing audits passed	23-09-05	CF
Crossject Completes European, US Audits for Manufacturing of Seizure Medication for US	23-09-05	MT
AFT Pharmaceuticals Secures Australia, New Zealand License for Epilepsy Rescue Medication	23-07-20	MT
Crossject Société Anonyme Signs New Licensing Agreement on Zeno Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand	23-07-20	CI

Chart Crossject

Duration

Period

More charts

Company Profile

Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

Sector

Medical Equipment, Supplies & Distribution

More about the company